Joel W. Hay, PhD
Faculty Directory

Joel W. HayPhD

Joel W. HayPhD

Professor of Pharmaceutical and Health Economics

Department of Pharmaceutical and Health Economics

Joel Hay is a professor in the Department of Pharmaceutical and Health Economics at the USC School of Pharmacy, with joint appointment the Department of Economics in the USC Dornsife College of Letters, Arts and Sciences. He is also a senior fellow in the USC Schaeffer Center for Health Policy & Economics and was founding chair of the former Department of Pharmaceutical Economics and Policy at the School of Pharmacy.

He serves as the USC project coordinator for the RAND Evidence-Based Medicine Practice Centers of Southern California, funded by the U.S. Agency for Health Research and Quality, and co-investigator at the USC Alzheimer Research Center, funded by the California Department of Health Services. He is a health economics research scholar at the UCLA Center for Vaccine Research and a founding executive board member of the American Society for Health Economics and of the International Society for Pharmaceutical Economics and Outcomes Research.

Hay was founding editor-in-chief of Value in Health, the peer-reviewed scientific journal of the International Society for Pharmacoeconomics and Outcomes Research, until 2003. This journal, started in 1998, became Medline-listed in 2002. Value in Health was ranked No. 1 in two categories for 2004 by the ISI Journal Citation Reports, with an impact factor of 3.657. Value in Health led all other journals listed both in the Health Care Sciences and Services category in the JCR Science edition and in the Health Policy & Services category in the JCR Social Sciences edition.

Hay has authored more than 600 peer-reviewed scientific articles, abstracts, editorials and reports in the fields of pharmaceutical economics, health economics, outcomes research, disease management, statistics, econometrics, epidemiology and healthcare.

Areas of Expertise

  • Drug Legalization
  • Pharmaceutical Economics
  • Health Economics
  • Econometrics
  • Outcomes Research
  • Pharmacoeconomics
  • Pharmaceutical Care
  • Health Care Markets
  • Health Insurance Reform
  • Sociological Costs of Drug and Alcohol Abuse
  • Education

    Yale University

    PhD

    Yale University

    MPhil

    Yale University

    MA

    Amherst College

    BA

  • Links
  • Selected Articles

    Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling

    Value Health
    Joel W. Hay

    2019 Peer-reviewed journals could make a key contribution to improving scientific rigor and real-world healthcare decision-maker acceptability by requiring that VHDM models, source code, and data used in published articles be made freely available to interested readers.

    Read More

    Cost-Effectiveness (CE) of Regorafenib Dose Optimization Schedule in Metastatic Colorectal Cancer

    Journal of Clinical Oncology
    Afsaneh Barzi, Sang K. Cho, Joel W. Hay, Heinz-Josef Lenz, Fang-Shu Ou, Axel Grothey, Tanios S. Bekaii-Saab

    2019 Based on the outcomes demonstrated in the ReDOS study, the dose optimization strategy of regorafenib results in favorable cost-effectiveness under a typical US willingness-to-pay threshold of $150,000 per QALY.

    Read More

    Total Cost of Care for Patients (pts) With Stage II Colon Cancer (CC-II): A Seer-Medicare Analysis

    Journal of Clinical Oncology
    Afsaneh Barzi, Xiayu Jiao, Joel W. Hay, Sarmad Sadeghi

    2019 Adjuvant chemotherapy (AC) for stage II colon cancer remains a controversial topic. We used Surveillance Epidemiology End Results (SEER) linkage with Medicare claims to explore the benefits of AC and cost of care in pts with CC-II diagnosed between 2004-2010.

    Read More

    Early Onset Sepsis Calculator-Based Management of Newborns Exposed to Maternal Intrapartum Fever: A Cost Benefit Analysis

    Journal of Perinatology
    Gong CL, Dasgupta-Tsinikas S, Zangwill KM, Bolaris M, Hay JW

    2019 This study determines the potential net monetary benefit of an early onset sepsis calculator-based approach for management of neonates exposed to maternal intrapartum fever, compared to existing guidelines.

    Read More

    Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: A Cost-Effectiveness Analysis

    Journal of General Internal Medicine
    Cynthia L. Gong, Kenneth M. Zangwill, Joel W. Hay, Daniella Meeker, Jason N. Doctor

    2018 This study determines the cost-effectiveness of three behavioral economic interventions designed to reduce inappropriate antibiotic prescriptions for ARIs.

    Read More

  • Affiliations
    • Academy of Managed Care Pharmacy

    • American Association of Colleges of Pharmacy

    • American Economic Association

    • American Public Health Association

    • American Society of Health Economists

  • Selected Media Appearances

    COVID-19 By Country

    RPubs | 04/15/2020

    Joel Hay led the development of a COVID-19 econometric model with country-specific logistic growth curves as functions of time from Day Zero (when the cumulative number of reported cases surpasses 100).

    Read More

    Has Sweden Found the Right Solution to the Coronavirus?

    National Review | 04/06/2020

    By Joel W. Hay, PhD and John Fund Unlike other countries, it has so far avoided both isolation and economic ruin.

    Read More

    Public Policy Panic About the COVID-19 Pandemic Not Supported by the Facts

    The Washington Times | 03/26/2020

    By Joel W. Hay, PhD and Cynthia L. Gong, PharmD, PhD Social isolation measures only for those at highest risk and aggressive contact tracing are more effective and less expensive than sending everyone home and shutting down the economy, Hay and Gong write.

    Read More

    A Cost-Effectiveness Analysis of Pre-Exposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex with Men

    USC Schaeffer Center | 12/01/2016

    By Joel W. Hay, PhD and Neeraj Sood, PhD In the ongoing fight against HIV and AIDS, PrEP and test-and-treat offer cost-effective alternatives to the status quo, with success depending on medication adherence and initiation rates.

    Read More